LRI Investments LLC Acquires 361 Shares of IQVIA Holdings Inc. $IQV

LRI Investments LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,071 shares of the medical research company’s stock after acquiring an additional 361 shares during the period. LRI Investments LLC’s holdings in IQVIA were worth $3,793,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Canada Pension Plan Investment Board raised its stake in shares of IQVIA by 7.3% in the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after buying an additional 312,807 shares during the period. JPMorgan Chase & Co. raised its stake in IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after acquiring an additional 798,534 shares during the period. American Century Companies Inc. raised its stake in IQVIA by 26.8% during the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after acquiring an additional 304,258 shares during the period. Dimensional Fund Advisors LP raised its stake in IQVIA by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after acquiring an additional 40,699 shares during the period. Finally, Pacer Advisors Inc. raised its position in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 2.3%

Shares of IQV opened at $198.35 on Friday. The company’s fifty day moving average is $189.02 and its 200 day moving average is $168.19. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34. The stock has a market capitalization of $33.72 billion, a PE ratio of 28.70, a P/E/G ratio of 2.18 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the previous year, the business posted $2.64 earnings per share. IQVIA’s quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday. Barclays lifted their target price on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Cowen reissued a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. HSBC raised IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $195.00 to $235.00 in a research note on Thursday. Finally, Robert W. Baird lifted their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $236.45.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.